Show simple item record

dc.contributor.authorJacquemier, J
dc.contributor.authorPadovani, L
dc.contributor.authorRabayrol, L
dc.contributor.authorLakhani, SR
dc.contributor.authorPenault-Llorca, F
dc.contributor.authorDenoux, Y
dc.contributor.authorFiche, M
dc.contributor.authorFigueiro, P
dc.contributor.authorMaisongrosse, V
dc.contributor.authorLedoussal, V
dc.contributor.authorPenuela, JM
dc.contributor.authorUdvarhely, N
dc.contributor.authorEl Makdissi, G
dc.contributor.authorGinestier, C
dc.contributor.authorGeneix, J
dc.contributor.authorCharafe-Jauffret, E
dc.contributor.authorXerri, L
dc.contributor.authorEisinger, F
dc.contributor.authorBirnbaum, D
dc.contributor.authorScree, EWGB
dc.contributor.authorHag, BCLC
dc.date.accessioned2018-09-05T15:09:20Z
dc.date.issued2005-11
dc.identifier3
dc.identifier.citationJOURNAL OF PATHOLOGY, 2005, 207 pp. 260 - 268
dc.identifier.issn0022-3417
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2563
dc.identifier.doi10.1002/path.1845
dc.description.abstractMedullary breast cancer (MBC) is a rare, diagnostically difficult, pathological subtype. Despite being high grade, it has a good prognosis. MBC patients have an excess of BRCA1 germ-fine mutation and reliable identification of MBC could help to identify patients at risk of carrying germline BRCA1 mutations or in whom chemotherapy could be avoided. The aim of this study was therefore to improve diagnosis by establishing an MBC protein expression profile using immunohistochemistry (IHC) on tissue-microarrays (TMA). Using a series of 779 breast carcinomas (’EC’ set), diagnosed initially as MBC, a double-reading session was carried out by several pathologists on all of the histological material to establish the diagnosis as firmly as possible using a ‘medullary score’. Only MBCs with high scores, i.e. typical MBC (TMBC) (n = 44) and non-TMBC grade III with no or low scores (n = 160), were included in the IHC study. To validate the results obtained on this first set, a control series of TMBC (n = 17) and non-MBC grade III cases (n = 140) (’IPC’ set) was studied. The expression of 18 proteins was studied in the 61 TMBCs and 300 grade III cases from the two sets. The global intra-observer concordance of the first reading for the diagnosis of TMBC was 94%, with almost perfect kappa (kappa) of 0.815. TMBC was characterized by a high degree of basal/myoepithelial differentiation. In multivariate analysis with logistic regression, TMBC was defined by the association of P-cadherin (R = 2.29), MIB1 > 50 (R = 3.80), ERBB2 negativity (R = 2.24) and p53 positivity (RR = 1.45). Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
dc.format.extent260 - 268
dc.languageeng
dc.language.isoeng
dc.publisherJOHN WILEY & SONS LTD
dc.titleTypical medullary breast carcinomas have a basal/myoepithelial phenotype
dc.typeJournal Article
rioxxterms.versionofrecord10.1002/path.1845
rioxxterms.licenseref.startdate2005-11
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJOURNAL OF PATHOLOGY
pubs.notesaffiliation: Jacquemier, J (Reprint Author), Inst J Paoli I Calmettes, Biopathol Dept, F-13009 Marseille, France. Inst J Paoli I Calmettes, Biopathol Dept, F-13009 Marseille, France. Marseille Canc Ist, Dept Mol Oncol, UMR599, INSERM, Marseille, France. Inst J Paoli I Calmettes, Genet Oncol & Canc Control Dept, F-13009 Marseille, France. Ctr Hosp Univ Timone, Dept Radiat Oncol, Marseille, France. Breakthrough Tony Robins Breast Canc Res Ctr, London, England. Univ Queensland, Sch Med, Brisbane, Qld, Australia. Jean Perrin Inst, Dept Pathol, Clermont Ferrand, France. Ctr Francois Baclesse, Dept Pathol, F-14021 Caen, France. Hop Laennec, Dept Pathol, St Herblain, France. Ctr Reg Oncol, Dept Pathol, Toulouse, France. Claudius Regaud Inst, Dept Pathol, Toulouse, France. Ctr Rene Huguenin, Dept Pathol, St Cloud, France. Hop Navarre, Dept Pathol, Pamplona, Spain. NCI, Dept Pathol, Budapest, Hungary. Univ Aix Marseille 2, Sch Med, F-13284 Marseille, France. keywords: breast cancer; medullary carcinoma; basal/myoepithelial differentiation; tissue microarrays; P-cadherin; Ki67; p53; ERBB2 keywords-plus: MYOEPITHELIAL CELL; EXPRESSION PATTERNS; ESTROGEN-RECEPTOR; CANCER CELLS; P-CADHERIN; FEATURES; IDENTIFICATION; CONSISTENCY; SUBCLASSES; PROGNOSIS research-areas: Oncology; Pathology web-of-science-categories: Oncology; Pathology author-email: [email protected] researcherid-numbers: Ginestier, Christophe/M-8828-2017 Lakhani, Sunil/I-1970-2018 Maisongrosse, Veronique/A-3748-2015 Collini, Paola/K-7354-2016 orcid-numbers: Lakhani, Sunil/0000-0003-4067-2760 Maisongrosse, Veronique/0000-0001-9315-7610 Schmitt, Fernando/0000-0002-3711-8681 Charafe-Jauffret, emmanuelle/0000-0002-0286-1299 Ginestier, Christophe/0000-0002-7477-3837 Schmitt, Fernando/0000-0003-1006-6946 Collini, Paola/0000-0002-6158-210X Eisinger, Francois/0000-0002-8794-0681 number-of-cited-references: 32 times-cited: 141 usage-count-last-180-days: 0 usage-count-since-2013: 6 journal-iso: J. Pathol. doc-delivery-number: 978SY unique-id: ISI:000232894500002 da: 2018-09-04
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Molecular Pathology
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Molecular Pathology
pubs.volume207en_US
pubs.embargo.termsNot known
icr.researchteamMolecular Pathologyen_US
dc.contributor.icrauthorLakhani, Sunilen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record